Skip to main content
Top
Published in: BMC Geriatrics 1/2016

Open Access 01-12-2016 | Study protocol

Protocol for a Prospective (P) study to develop a model to stratify the risk (RI) of medication (M) related harm in hospitalized elderly (E) patients in the UK (The PRIME study)

Authors: Jennifer Stevenson, Nikesh Parekh, Khalid Ali, Jean Timeyin, Stephen Bremner, Tischa Van Der Cammen, Jane Allen, Rebekah Schiff, Jatinder Harchowal, Graham Davies, Chakravarthi Rajkumar

Published in: BMC Geriatrics | Issue 1/2016

Login to get access

Abstract

Background

Medication related harm (MRH) is a common cause of morbidity and hospital admission in the elderly, and has significant cost implications for both primary and secondary healthcare resources. The development of risk prediction models has become an increasingly common phenomenon in medicine and can be useful to guide objective clinical decision making, resource allocation and intervention. There are no risk prediction models that are widely used in clinical practice to identify elderly patients at high risk of MRH following hospital discharge. The aim of this study is to develop a risk prediction model (RPM) to identify elderly patients at high risk of MRH upon discharge from hospital, and to compare this with routine clinical judgment.

Methods/Design

This is a multi-centre, prospective observational study following a cohort of patients for 8 weeks after hospital discharge. Data collection including patient characteristics, medication use, social factors and frailty will take place prior to patient discharge and then the patient will be followed up in the community over the next 8 weeks to determine if they have experienced MRH. Research pharmacists will determine whether patients have experienced MRH by prospectively reviewing records for unplanned emergency department attendance, hospital readmission and GP consultation related to MRH. Research pharmacists will also telephone patients directly to determine self-reported MRH, which patients may not have sought further medical attention for. The data collected will inform the development of a RPM which will be externally validated in a follow-up study.

Discussion

There are no RPMs that are used in clinical practice to help stratify elderly patients at high risk of MRH in the community following hospital discharge, despite this being a significant public health problem. This study plans to develop a clinically useful RPM that is better than routine clinical judgment. As this is a multi-centre study involving clinical settings that serve elderly people of heterogeneous sociodemographic background, it is anticipated that this RPM will be generalizable.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tangiisuran B, Gozzoli MP, Davies JG, Rajkumar C. Adverse drug reactions in older people. Rev Clin Gerontol. 2010;20:246–59.CrossRef Tangiisuran B, Gozzoli MP, Davies JG, Rajkumar C. Adverse drug reactions in older people. Rev Clin Gerontol. 2010;20:246–59.CrossRef
2.
go back to reference Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.PubMedPubMedCentralCrossRef Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329(7456):15–9.PubMedPubMedCentralCrossRef
3.
go back to reference Tangiisuran B, Davies JG, Wright JE, Rajkumar C. Adverse drug reactions in a population of hospitalized very elderly patients. Drugs Aging. 2012;29(8):669–79.PubMed Tangiisuran B, Davies JG, Wright JE, Rajkumar C. Adverse drug reactions in a population of hospitalized very elderly patients. Drugs Aging. 2012;29(8):669–79.PubMed
4.
go back to reference Mannesse CK, Derkx FH, de Ridder MA, Man in ’t Veld AJ, van der Cammen TJ. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing. 2000;29(1):35–9.PubMedCrossRef Mannesse CK, Derkx FH, de Ridder MA, Man in ’t Veld AJ, van der Cammen TJ. Contribution of adverse drug reactions to hospital admission of older patients. Age Ageing. 2000;29(1):35–9.PubMedCrossRef
5.
go back to reference Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalization for adverse drug events in older americans. N Eng J Med. 2011;365:2002–12.CrossRef Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalization for adverse drug events in older americans. N Eng J Med. 2011;365:2002–12.CrossRef
6.
go back to reference Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.PubMedCrossRef Beijer HJ, de Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46–54.PubMedCrossRef
7.
go back to reference Petrovic M, van der Cammen T, Onder G. Adverse drug reactions in older people. Drugs Aging. 2012;29:453–62.PubMedCrossRef Petrovic M, van der Cammen T, Onder G. Adverse drug reactions in older people. Drugs Aging. 2012;29:453–62.PubMedCrossRef
8.
go back to reference Onder G, Petrovic M, Tangiisuran B, Meinardi MC, Markito-Notenboom WP, Somers A, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients aged 65 or older. The GerontoNet ADR risk score. Arch Int Med. 2010;170(13):1142–8.CrossRef Onder G, Petrovic M, Tangiisuran B, Meinardi MC, Markito-Notenboom WP, Somers A, et al. Development and validation of a score to assess risk of adverse drug reactions among in-hospital patients aged 65 or older. The GerontoNet ADR risk score. Arch Int Med. 2010;170(13):1142–8.CrossRef
9.
go back to reference Tangiisuran B, Scutt G, Stevenson J, Wright J, Onder G, Petrovic M, et al. Development and Validation of a Risk Model for Predicting Adverse Drug Reactions in Older People during Hospital Stay: Brighton Adverse Drug Reactions Risk (BADRI) Model. PLOS ONE. 2014: 9(10). doi:10.1371/journal.pone.0111254 Tangiisuran B, Scutt G, Stevenson J, Wright J, Onder G, Petrovic M, et al. Development and Validation of a Risk Model for Predicting Adverse Drug Reactions in Older People during Hospital Stay: Brighton Adverse Drug Reactions Risk (BADRI) Model. PLOS ONE. 2014: 9(10). doi:10.​1371/​journal.​pone.​0111254
10.
go back to reference McElnay JC, McCallion CR, Al-Deagi F, Scott MG. Development of a risk model for adverse drug events. Clin Drug Invest. 1997;13:47–55.CrossRef McElnay JC, McCallion CR, Al-Deagi F, Scott MG. Development of a risk model for adverse drug events. Clin Drug Invest. 1997;13:47–55.CrossRef
11.
go back to reference Trivalle C, Burlaud A, The IMEPAG Group 1, Ducimetiere P. Risk factors for adverse drug events in hospitalized elderly patients: a geriatric score. Eur Geriatr Med. 2011;2:284–9.CrossRef Trivalle C, Burlaud A, The IMEPAG Group 1, Ducimetiere P. Risk factors for adverse drug events in hospitalized elderly patients: a geriatric score. Eur Geriatr Med. 2011;2:284–9.CrossRef
12.
go back to reference Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergence re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol. 2010;70(5):749–55.PubMedPubMedCentralCrossRef Davies EC, Green CF, Mottram DR, Rowe PH, Pirmohamed M. Emergence re-admissions to hospital due to adverse drug reactions within 1 year of the index admission. Br J Clin Pharmacol. 2010;70(5):749–55.PubMedPubMedCentralCrossRef
14.
go back to reference Medical Research Council. Developing and Evaluating Complex Interventions: new Guidance. London: MRC; 2008. Medical Research Council. Developing and Evaluating Complex Interventions: new Guidance. London: MRC; 2008.
15.
go back to reference Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Ann Pharmacother. 1990;24(11):1093–7. Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GD. Drug-related problems: their structure and function. Ann Pharmacother. 1990;24(11):1093–7.
16.
go back to reference Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423–9.PubMedCrossRef Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing. 2011;40(4):423–9.PubMedCrossRef
17.
go back to reference Henderson S, Moore N, Lee E, Witham M. Do the malnutrition universal screening tool (MUST) and Birmingham nutrition risk (BNR) score predict mortality in older hospitalized patients? BMC Geriatr. 2008;8:26.PubMedPubMedCentralCrossRef Henderson S, Moore N, Lee E, Witham M. Do the malnutrition universal screening tool (MUST) and Birmingham nutrition risk (BNR) score predict mortality in older hospitalized patients? BMC Geriatr. 2008;8:26.PubMedPubMedCentralCrossRef
18.
go back to reference Mahoney F, Barthel D. Functional evaluation: the Barthel index. Md Med J. 1965;14:61–5. Mahoney F, Barthel D. Functional evaluation: the Barthel index. Md Med J. 1965;14:61–5.
19.
go back to reference National Patient Safety Agency (NPSA). A risk matrix for risk managers. 2008. National Patient Safety Agency (NPSA). A risk matrix for risk managers. 2008.
20.
go back to reference Naranjo C, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRef Naranjo C, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–45.PubMedCrossRef
21.
go back to reference Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.PubMedCrossRef Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.PubMedCrossRef
22.
23.
go back to reference Buderer NM. Statistical methodology; 1: Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med. 1996;3:895–900.PubMedCrossRef Buderer NM. Statistical methodology; 1: Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity. Acad Emerg Med. 1996;3:895–900.PubMedCrossRef
24.
go back to reference Steyerberg EW, Eijkemans MJ, Harrell FE, Habema JD. Prognostic modelling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Dec Making. 2001;21(1):45–56.CrossRef Steyerberg EW, Eijkemans MJ, Harrell FE, Habema JD. Prognostic modelling with logistic regression analysis: in search of a sensible strategy in small data sets. Med Dec Making. 2001;21(1):45–56.CrossRef
25.
go back to reference Steyerberg EW. Clinical Prediction Models. A Practical Approach to Development, Validation and Updating. 1st ed. Berlin: Springer; 2009. Steyerberg EW. Clinical Prediction Models. A Practical Approach to Development, Validation and Updating. 1st ed. Berlin: Springer; 2009.
26.
go back to reference Stevenson JM, Williams JL, Burnham TG, Prevost AT, Schiff R, Erskine SD, et al. Predicting adverse drug reactions in older adults; a systematic review of the risk prediction models. Clin Int Aging. 2014;9:1581–93.CrossRef Stevenson JM, Williams JL, Burnham TG, Prevost AT, Schiff R, Erskine SD, et al. Predicting adverse drug reactions in older adults; a systematic review of the risk prediction models. Clin Int Aging. 2014;9:1581–93.CrossRef
Metadata
Title
Protocol for a Prospective (P) study to develop a model to stratify the risk (RI) of medication (M) related harm in hospitalized elderly (E) patients in the UK (The PRIME study)
Authors
Jennifer Stevenson
Nikesh Parekh
Khalid Ali
Jean Timeyin
Stephen Bremner
Tischa Van Der Cammen
Jane Allen
Rebekah Schiff
Jatinder Harchowal
Graham Davies
Chakravarthi Rajkumar
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Geriatrics / Issue 1/2016
Electronic ISSN: 1471-2318
DOI
https://doi.org/10.1186/s12877-016-0191-8

Other articles of this Issue 1/2016

BMC Geriatrics 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.